383 related articles for article (PubMed ID: 28039473)
1. Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity.
Mazzucchelli S; Bellini M; Fiandra L; Truffi M; Rizzuto MA; Sorrentino L; Longhi E; Nebuloni M; Prosperi D; Corsi F
Oncotarget; 2017 Jan; 8(5):8383-8396. PubMed ID: 28039473
[TBL] [Abstract][Full Text] [Related]
2. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
3. Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay.
Zhang C; Wu Y; Dong Y; Xu H; Zhao L
Pharm Biol; 2016; 54(1):55-61. PubMed ID: 25880143
[TBL] [Abstract][Full Text] [Related]
4. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.
Kwak G; Jo SD; Kim D; Kim H; Kim MG; Kim K; Kwon IC; Kim SH
J Control Release; 2017 Dec; 267():203-213. PubMed ID: 28823674
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
7. TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer.
Cheng X; Fan K; Wang L; Ying X; Sanders AJ; Guo T; Xing X; Zhou M; Du H; Hu Y; Ding H; Li Z; Wen X; Jiang W; Yan X; Ji J
Cell Death Dis; 2020 Feb; 11(2):92. PubMed ID: 32024821
[TBL] [Abstract][Full Text] [Related]
8. Smart doxorubicin nanoparticles with high drug payload for enhanced chemotherapy against drug resistance and cancer diagnosis.
Yu C; Zhou M; Zhang X; Wei W; Chen X; Zhang X
Nanoscale; 2015 Mar; 7(13):5683-90. PubMed ID: 25740312
[TBL] [Abstract][Full Text] [Related]
9. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.
Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F
Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496
[TBL] [Abstract][Full Text] [Related]
10. Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth.
Li M; Sala V; De Santis MC; Cimino J; Cappello P; Pianca N; Di Bona A; Margaria JP; Martini M; Lazzarini E; Pirozzi F; Rossi L; Franco I; Bornbaum J; Heger J; Rohrbach S; Perino A; Tocchetti CG; Lima BHF; Teixeira MM; Porporato PE; Schulz R; Angelini A; Sandri M; Ameri P; Sciarretta S; Lima-Júnior RCP; Mongillo M; Zaglia T; Morello F; Novelli F; Hirsch E; Ghigo A
Circulation; 2018 Aug; 138(7):696-711. PubMed ID: 29348263
[TBL] [Abstract][Full Text] [Related]
11. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
Zeng X; Morgenstern R; Nyström AM
Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
16. Enhancing the Antitumor Effect of Doxorubicin with Photosensitive Metal-Organic Framework Nanoparticles against Breast Cancer.
Jiang Q; Zhang M; Sun Q; Yin D; Xuan Z; Yang Y
Mol Pharm; 2021 Aug; 18(8):3026-3036. PubMed ID: 34213912
[TBL] [Abstract][Full Text] [Related]
17. Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy.
Zhang C; Pan D; Luo K; She W; Guo C; Yang Y; Gu Z
Adv Healthc Mater; 2014 Aug; 3(8):1299-308. PubMed ID: 24706635
[TBL] [Abstract][Full Text] [Related]
18. A folate modified pH sensitive targeted polymeric micelle alleviated systemic toxicity of doxorubicin (DOX) in multi-drug resistant tumor bearing mice.
Li X; Yang X; Lin Z; Wang D; Mei D; He B; Wang X; Wang X; Zhang Q; Gao W
Eur J Pharm Sci; 2015 Aug; 76():95-101. PubMed ID: 25917524
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-induced co-assembling nanomedicines with temperature-sensitive acidic polymer and their in-situ-forming hydrogels for intratumoral administration.
Wan J; Geng S; Zhao H; Peng X; Zhou Q; Li H; He M; Zhao Y; Yang X; Xu H
J Control Release; 2016 Aug; 235():328-336. PubMed ID: 27282415
[TBL] [Abstract][Full Text] [Related]
20. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects.
Lages EB; Fernandes RS; Andrade MMS; Paiyabhroma N; de Oliveira RB; Fernandes C; Cassali GD; Sicard P; Richard S; Branco de Barros AL; Ferreira LAM
Biomed Pharmacother; 2021 Dec; 144():112373. PubMed ID: 34794238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
